Ranjana Tavorath

Oncology
1 Health Plz
East Hanover, NJ 07936

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Journal: The oncologist
Published: August 08, 2017

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Journal: Haematologica
Published: April 14, 2017

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.

Journal: OncoTargets and therapy
Published: January 22, 2016
Showing 1-3 of 3

Last Updated: 09/26/2026